Absence of p51 mutation in human hepatocellular carcinoma

被引:4
作者
Hamada, K
Koyama, T
Shimizu, K
Ikawa, S
Kawate, S
Yokota, J
Ohwada, S
Morishita, Y
机构
[1] Gunma Univ, Sch Med, Dept Surg 2, Gunma 3718511, Japan
[2] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan
[3] Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9800872, Japan
关键词
p51; gene; p53; family; mutation; hepatocellular carcinoma;
D O I
10.1016/S0304-3835(99)00330-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p51 gene encodes a protein with significant homology to p53. To investigate the involvement of the p51 gene in human hepatocarcinogenesis, mutation analysis of the p51 gene was performed in 54 cases of hepatocellular carcinoma (HCC). No mutations causing amino acid substitutions or frameshifts were found by polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis of the entire coding region. The result indicated that mutation of the p51 gene does not play a major role in the development of HCC in Japanese patients. Further studies on p51 expression and its functions, including the interaction with p53, are necessary to elucidate the role of the p51 gene in human hepatocarcinogenesis. (C) 2000 Elsevier Science Ireland Ltd, All rights reserved.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 20 条
[11]  
ODA T, 1992, CANCER RES, V52, P6354
[12]   Cloning and functional analysis of human p51, which structurally and functionally resembles p53 [J].
Osada, M ;
Ohba, M ;
Kawahara, C ;
Ishioka, C ;
Kanamaru, R ;
Katoh, I ;
Ikawa, Y ;
Nimura, Y ;
Nakagawara, A ;
Obinata, M ;
Ikawa, S .
NATURE MEDICINE, 1998, 4 (07) :839-843
[13]   TRANSFORMING GENE FROM HUMAN STOMACH CANCERS AND A NON-CANCEROUS PORTION OF STOMACH MUCOSA [J].
SAKAMOTO, H ;
MORI, M ;
TAIRA, M ;
YOSHIDA, T ;
MATSUKAWA, S ;
SHIMIZU, K ;
SEKIGUCHI, M ;
TERADA, M ;
SUGIMURA, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (11) :3997-4001
[14]   A second p53-related protein, p73L, with high homology to p73 [J].
Senoo, M ;
Seki, N ;
Ohira, M ;
Sugano, S ;
Watanabe, M ;
Tachibana, M ;
Tanaka, T ;
Shinkai, Y ;
Kato, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (03) :603-607
[15]   Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma [J].
Shiota, G ;
Kishimoto, Y ;
Suyama, A ;
Okubo, M ;
Katayama, S ;
Harada, K ;
Ishida, M ;
Hori, K ;
Suou, T ;
Kawasaki, H .
JOURNAL OF HEPATOLOGY, 1997, 27 (04) :661-668
[16]   Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer [J].
Sunahara, M ;
Shishikura, T ;
Takahashi, M ;
Todo, S ;
Yamamoto, N ;
Kimura, H ;
Kato, S ;
Ishioka, C ;
Ikawa, S ;
Ikawa, Y ;
Nakagawara, A .
ONCOGENE, 1999, 18 (25) :3761-3765
[17]  
Tani Masachika, 1999, Neoplasia (New York), V1, P71, DOI 10.1038/sj.neo.7900008
[18]  
TORNALETTI S, 1995, ONCOGENE, V10, P1493
[19]   A new human p53 homologue [J].
Trink, B ;
Okami, K ;
Wu, L ;
Sriuranpong, V ;
Jen, J ;
Sidransky, D .
NATURE MEDICINE, 1998, 4 (07) :747-748
[20]   p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities [J].
Yang, AN ;
Kaghad, M ;
Wang, YM ;
Gillett, E ;
Fleming, MD ;
Dotsch, V ;
Andrews, NC ;
Caput, D ;
McKeon, F .
MOLECULAR CELL, 1998, 2 (03) :305-316